Research graph
References from Mechanistic exploration of 4-bromobenzyloxy-1,2,3-triazole derivatives as dual cholinesterase inhibitors: Kinetic, molecular dynamics, and halogen-contact insights. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1063/1.464913
10.1063/1.464913 · External reference
Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension
10.2165/00002512-199812030-00005 · 1998 · External reference
Scaffold hopping strategy toward novel Pyrazolo[3,4-d]pyrimidine-based thiazole frameworks as potential cholinesterase inhibitors for treating Alzheimer’s disease: insight into in vitro and in silico approaches
10.1016/j.molstruc.2026.145424 · 2026 · External reference
10.1002/alz.70235
10.1002/alz.70235 · External reference
10.1093/nar/gkae303
10.1093/nar/gkae303 · External reference
Comprehensive review on Alzheimer’s Disease: causes and treatment
10.3390/molecules25245789 · 2020 · External reference
Synthesis, molecular docking and some metabolic enzyme inhibition properties of biphenyl-substituted chalcone derivatives
10.1016/j.molstruc.2022.132358 · 2022 · External reference
The halogen bond
10.1021/acs.chemrev.5b00484 · 2016 · External reference
Novel hybrid structures based on 4-Chlorobenzenesulfonyl and 1,2,3-triazoles: Synthesis, in vitro biological activities and in silico studies
10.1016/j.molliq.2024.125501 · 2024 · External reference
Novel hybrid structures based on 4-Chlorobenzenesulfonyl and 1,2,3-triazoles: Synthesis, in vitro biological activities and in silico studies
10.1016/j.molliq.2024.125501 · 2024 · External reference
Synthesis and bioactivity evaluation of novel sulfonamide-1,2,3-triazole hybrids: in vitro and in silico studies
10.1111/cbdd.70155 · 2025 · External reference
Acetylcholinesterase inhibitors: pharmacology and toxicology
10.2174/1570159x11311030006 · 2013 · External reference
A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors
10.1042/bj1370143 · 1974 · External reference
Small-molecule library screening by docking with PyRx
10.1007/978-1-4939-2269-7_19 · 2015 · External reference
Butyrylcholinesterase as a diagnostic and therapeutic target for Alzheimer’s disease
10.2174/1567205013666160404120542 · 2016 · External reference
The determination of enzyme inhibitor constants
10.1042/bj0550170 · 1953 · External reference
Acetylcholinesterase: from 3D structure to function
10.1016/j.cbi.2010.01.042 · 2010 · External reference
Management of acute organophosphorus pesticide poisoning
10.1016/s0140-6736(07)61202-1 · 2008 · External reference
Three novel 1,2,3-triazole-fused compounds: Syntheses, structural and spectroscopic characterizations with molecular modeling
10.1016/j.molstruc.2023.137207 · 2024 · External reference
A new and rapid colorimetric determination of acetylcholinesterase activity
10.1016/0006-2952(61)90145-9 · 1961 · External reference
Novel dibenzoazepine-substituted triazole hybrids as cholinesterase and carbonic anhydrase inhibitors and anticancer agents: synthesis, characterization, biological evaluation, and in silico studies
10.1021/acsomega.4c05804 · 2024 · External reference
Unresolved reference
External reference
Kinetic model of ethopropazine interaction with horse serum butyrylcholinesterase and its docking into the active site
10.1006/abbi.2001.2697 · 2002 · External reference
Triazoles in medicinal chemistry: physicochemical properties, bioisosterism, and application
10.1021/acs.jmedchem.4c00652 · 2024 · External reference
Facile halogenation of antimicrobial peptides as demonstrated by producing bromotryptophan-labeled nisin variants with enhanced antimicrobial activity
10.1021/acs.jnatprod.4c00118 · 2024 · External reference
Acetylcholinesterase: structure, dynamics, and interactions with organophosphorus compounds
10.1002/pro.70297 · 2025 · External reference
Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer’s fibrils: Possible role of the peripheral site of the enzyme
10.1016/s0896-6273(00)80108-7 · 1996 · External reference
Prediction of drug solubility from structure
10.1016/s0169-409x(02)00008-x · 2002 · External reference
Evidence linking protein misfolding to quality control in progressive neurodegenerative diseases
10.2174/1568026620666200618114924 · 2020 · External reference
An overview of 1,2,3-triazole-containing hybrids and their potential anticholinesterase activities
10.3390/ph16020179 · 2023 · External reference
10.1142/s2737416526500067
10.1142/s2737416526500067 · External reference
A comprehensive computational and experimental study of novel imidazole linked thiadiazole based amide derivatives as cholinesterase duel-target inhibitor for the treatment of Alzheimer’s disease
10.1016/j.compbiolchem.2025.108789 · 2026 · External reference
Design, synthesis and biological profiling of bis-thiazole linked Schiff bases as effective enzyme inhibitors for targeting urease and thymidine phosphorylase proteins
10.1007/s00210-025-04879-1 · 2026 · External reference
Alzheimer disease
2021 · External reference
Structure of acetylcholinesterase complexed with E2020 (Ariceptρ): Implications for the design of new anti-Alzheimer drugs
10.1016/s0969-2126(99)80040-9 · 1999 · External reference
10.1103/physrevb.37.785
10.1103/physrevb.37.785 · External reference
Review of triazole scaffolds for treatment and diagnosis of Alzheimer’s disease
10.1016/j.cbi.2023.110623 · 2023 · External reference
The determination of enzyme dissociation constants
10.1021/ja01318a036 · 1934 · External reference
Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions
10.1016/j.addr.2016.04.029 · 2016 · External reference
Progress in synthetic trends followed for the development of 1,2,3-triazole derivatives: a review
10.1080/10406638.2023.2247119 · 2024 · External reference
Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design
10.1021/jm1013693 · 2011 · External reference
Synthesis, design, and cholinesterase inhibitory activity of novel 1,2,4-triazole Schiff bases: a combined experimental and computational approach
10.1016/j.ijbiomac.2025.141350 · 2025 · External reference
Purification and determination of the amino acid sequence of equine serum butyrylcholinesterase
10.1080/105172399242573 · 1999 · External reference
Evaluation of novel nitrophenol-triazole hybrid molecules: biological screening and computational profiling
10.1080/17568919.2025.2539674 · 2025 · External reference
Exploring the multi-faceted potential of novel p-cresol-triazole hybrids: anticancer, anticholinesterase, and antioxidant properties with in silico insights
10.1016/j.bioorg.2025.108916 · 2025 · External reference
Multifunctional hydroquinone–1,2,3-triazole hybrids: Synthesis, biological evaluation, molecular docking, ADMET profiling, and in silico mechanistic insights as potential therapeutic agents
10.1016/j.bioorg.2026.109548 · 2026 · External reference
Efficient, rapid, and high-yield synthesis of aryl Schiff base derivatives and their in vitro and in silico inhibition studies of hCA I, hCA II, AChE, and BuChE
2024 · External reference
Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis
10.2165/00003495-198020040-00001 · 1980 · External reference
Converting peptides into drugs targeting intracellular protein–protein interactions
10.1016/j.drudis.2021.01.022 · 2021 · External reference
Assessment of acetylcholinesterase activity using indoxylacetate and comparison with the standard Ellman’s method
10.3390/ijms12042631 · 2011 · External reference
Introducing bromine to the molecular structure as a strategy for drug design
2024 · External reference
10.1016/b978-0-323-95702-1.00119-6
10.1016/b978-0-323-95702-1.00119-6 · External reference
Halogenated inhalational anaesthetics
10.1053/bean.2002.0265 · 2003 · External reference
10.1002/1521-3773(20020715)41:14<2596::aid-anie2596>3.0.co;2-4
10.1002/1521-3773(20020715)41:14<2596::aid-anie2596>3.0.co;2-4 · External reference
New sulfonamide derivatives based on 1,2,3-triazoles: synthesis, in vitro biological activities and in silico studies
10.1080/07391102.2023.2222833 · 2024 · External reference
Design and synthesis of 1,4-disubstituted 1,2,3-triazoles: Biological evaluation, in silico molecular docking and ADME screening
10.1016/j.molstruc.2021.131344 · 2022 · External reference
Design and synthesis of 1,4-disubstituted 1,2,3-triazoles: Biological evaluation, in silico molecular docking and ADME screening
10.1016/j.molstruc.2021.131344 · 2022 · External reference
Triazole based novel molecules as potential therapeutic agents: Synthesis, characterization, biological evaluation, in-silico ADME profiling and molecular docking studies
10.1016/j.cbi.2022.110312 · 2023 · External reference
Discovery of new 1,4-disubstituted 1,2,3-triazoles: in silico ADME profiling, molecular docking and biological evaluation studies
10.1080/07391102.2022.2025905 · 2023 · External reference
Differences in active-site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase
10.1016/s0009-2797(99)00014-9 · 1999 · External reference
Unresolved reference
External reference
10.1007/s10822-007-9133-z
10.1007/s10822-007-9133-z · External reference
Unresolved reference
External reference
Discovery of cinnamamide/ester triazole hybrids as potential treatment for Alzheimer’s disease
10.1016/j.bioorg.2024.107584 · 2024 · External reference
Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides
10.1021/jo011148j · 2002 · External reference
Thiol bearing aryl Schiff bases of 2-aminothiophenol as acetylcholinesterase and butyrylcholinesterase inhibitors
10.1515/pac-2026-0756 · 2026 · External reference
K.W. Lewis, Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer’s Disease
10.1001/jama.1994.03510370044030 · 1994 · External reference
Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction
10.1016/0006-2952(73)90196-2 · 1973 · External reference
